Serum triglycerides, HIV infection, and highly active antiretroviral therapy, Aquitaine Cohort, France, 1996 to 1998

Journal of Acquired Immune Deficiency Syndromes

Volumn 23, Issue 3, 2000, Pages 261-265

  Thiebaut R ^a   Dabis, F ^a   Malvy, D ^b   Jacqmin Gadda, H ^a   Mercie P ^b   Daucourt Valentin, V ^a,b  

^a INSERM   (France)

^b BORDEAUX UNIVERSITY HOSPITAL   (France)

Author keywords

HIV infection; Longitudinal studies; Protease inhibitors; Triglycerides

Indexed keywords

INDINAVIR; NELFINAVIR; RITONAVIR; SAQUINAVIR;

ADULT; AGE; ARTICLE; BODY WEIGHT; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTRIGLYCERIDEMIA; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SEX DIFFERENCE; VIRUS LOAD;

EID: 0034162171     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-200003010-00009     Document Type: Article

References (32)

1. Grunfeld C, Pang M, Doerrler W, Shigenaga JK, Jensen P, Feingold KR. Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metab 1992;74: 1045-52.
2. Constans J, Pellegrin JL, Peuchant E, et al. Plasma lipids in HIV-infected patients: a prospective study in 95 patients. Ear J Clin Invest 1994;24:416-20.
3. Grunfeld C, Kotler DP, Shigenaga JK, et al. Circulating interferonalpha levels and hypertriglyceridemia in the acquired immunodeficiency syndrome. Am J Med 1991;90:154-62.
4. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998;12:F51-8.
5. Miller KD, Jones E, Yanovski JA, Shankar R, Feuerstein I, Falloon J. Visceral abdominal-fat accumulation associated with use of indinavir. Lancet 1998;351:871-5.
6. Walli R, Herfort O, Michl GM, et al. Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients. AIDS 1998;12:F167-73.
7. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999;353:2093-9.
8. Martinez E, Gatell J. Metabolic abnormalities and use of HIV-1 protease inhibitors. Lancet 1998;352:821-2.
9. Markowitz M, Saag M, Powderly WG, et al. A preliminary study of ritonavir, an inhibitor of HIV-I protease, to treat HIV-1 infection. N Engl J Med 1995;333:1534-9.
10. Sullivan AK, Nelson MR. Marked hyperlipidaemia on ritonavir therapy. AIDS 1997;11:938-9.
11. Perry RC, Cushing HE, Deeg MA, Prince MJ. Ritonavir, triglycerides, and pancreatitis. Clin Infect Dis 1999;28:161-2.
12. Austin MA. Plasma triglyceride as a risk factor for coronary heart disease. The epidemiologic evidence and beyond. Am J Epidemiol 1989;129:249-59.
13. Henry K, Melroe H, Huebsch J, et al. Severe premature coronary artery disease with protease inhibitors. Lancet 1998;351:1328.
14. Feingold KR, Krauss RM, Pang M, Doerrler W, Jensen P, Grunfeld C. The hypertriglyceridemia of acquired immunodeficiency syndrome is associated with an increased prevalence of low density Iipoprotein subclass pattern B. J Clin Endocrinol Metab 1993;76: 1423-7.
15. Marimoutou C, Chene G, Dabis F, Lacoste D, Salamon R. Human immunodeficiency virus infection and AIDS in Aquitaine. 10 years' experience of a hospital information system, 1985-1995. Le Groupe d'Epidemiologie Clinique du SIDA en Aquitaine (GECSA) [in French]. Presse Med 1997;26:703-10.
16. Laird NM, Ware JH. Random-effects models for longitudinal data. Biometrics 1982;38:963-74.
17. Direction Générale de la Santé. Révision de la définition du SIDA en France [in French]. Bull Epidemiol Hebd 1993;1-2.
18. Christeff N, Lortholary O, Casassus P, et al. Serum lipid concentration with reference to the clinical and immunological status of HIV infected men. Ann Med Interne (Paris) 1995;146:490-5.
19. Danner SA, Carr A, Leonard JM, et al. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European-Australian Collaborative Ritonavir Study Group. N Engl J Med 1995;333:1528-33.
20. Churchill DR, Pym AS, Babiker AG, Back DJ, Weber JN. Hyperlipidaemia following treatment with protease inhibitors in patients with HIV-1 infection. Br J Clin Pharmacol 1998;46:518-19.
21. Merry C, Barry MG, Mulcahy F, et al. Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV-infected patients. AIDS 1997;11:F29-33.
22. Moyle GJ, Baldwin C. Lipid abnormalities during saquinavir softgel-based highly active antiretroviral therapy [letter]. JAIDS J Acquir Immune Defic Syndr 1999;21:423-1.
23. Martinez E, Conget I, Lozano L, Casamitjana R, Gatell JM. Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine. AIDS 1999;13:805-810.
24. Lo JC, Mulligan K, Tai VW, Algren H, Schambelan M. "Buffalo hump" in men with HIV-1 infection. Lancet 1998;351:867-70.
25. Gervasoni C, Ridolfo AL, Trifiro G, et al. Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy. AIDS 1999;13:465-71.
26. Saint-Marc T, Partisani M, Poizot-Martin I, et al. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy. AIDS 1999;13:1659-67.
27. Carr A, Samaras K, Chisholm DJ, Cooper DA. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet 1998;351:1881-3.
28. Tsiodras S, Mantzoros C, Hammer SM, Samore M. Effects of protease inhibitor use on hyperglycemia and hyperlipidemia: a five year analysis [abstract 643]. Presented at the 6th Conference on Retroviruses and Opportunistic Infections, Chicago, 1999.
29. Stricker RB, Goldberg B. Weight gain associated with protease inhibitor therapy in HIV-infected patients. Res Virol 1998;149: 123-6.
30. Kotler DP, Rosenbaum K, Wang J, Pierson RN. Studies of body composition and fat distribution in HIV-infected and control subjects. JAIDS J Acquir Immune Defic Syndr 1999;20:228-37.
31. Silva M, Skolnik PR, Gorbach SL, et al. The effect of protease inhibitors on weight and body composition in HIV-infected patients. AIDS 1998;12:1645-51.
32. Foster CJ, Weinsier RL, Birch R, et al. Obesity and serum Iipids: an evaluation of the relative contribution of body fat and fat distribution to lipid levels. Int J Obes 1987;11:151-61.